Precision medicine advances in idiopathic pulmonary fibrosis

T Karampitsakos, BM Juan-Guardela, A Tzouvelekis… - …, 2023 - thelancet.com
Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …

The therapy of idiopathic pulmonary fibrosis: what is next?

V Somogyi, N Chaudhuri, SE Torrisi… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease?

AJ Byrne, TM Maher, CM Lloyd - Trends in molecular medicine, 2016 - cell.com
Pulmonary fibrosis (PF) is a growing clinical problem which can result in breathlessness or
respiratory failure and has an average life expectancy of 3 years from diagnosis …

[HTML][HTML] The therapeutic potential of galectin-3 inhibition in fibrotic disease

RJ Slack, R Mills, AC Mackinnon - … Journal of Biochemistry & Cell Biology, 2021 - Elsevier
Galectin-3 is a beta-galactoside-binding mammalian lectin and part of the 15 member
galectin family that are evolutionarily highly conserved. It is the only chimeric protein with a …

Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis

M Kreuter, JS Lee, A Tzouvelekis… - American journal of …, 2021 - atsjournals.org
Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for
idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count …

Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways

CM Evans, TE Fingerlin, MI Schwarz… - Physiological …, 2016 - journals.physiology.org
Idiopathic pulmonary fibrosis (IPF) is an incurable complex genetic disorder that is
associated with sequence changes in 7 genes (MUC5B, TERT, TERC, RTEL1, PARN …

Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development

AV Samarelli, V Masciale, B Aramini, GP Coló… - International journal of …, 2021 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

[HTML][HTML] Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype

Y Inoue, RJ Kaner, J Guiot, TM Maher, S Tomassetti… - Chest, 2020 - Elsevier
Biomarkers have the potential to become central to the clinical evaluation and monitoring of
patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype …

Blood biomarkers in idiopathic pulmonary fibrosis

J Guiot, C Moermans, M Henket, JL Corhay, R Louis - Lung, 2017 - Springer
Purpose Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease of
unknown origin whose incidence has been increasing over the latest decade partly as a …

[HTML][HTML] Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis

S Ohshimo, N Ishikawa, Y Horimasu, N Hattori… - Respiratory …, 2014 - Elsevier
Background Acute exacerbation (AE) is a major cause of death in idiopathic pulmonary
fibrosis (IPF). However, little is known about sensitive biomarkers for predicting AE. The aim …